**RESEARCH ARTICLE**

**Antimicrobial Efficacy of Silymarin and Silibinin Against Oral Microorganisms**

Murali Iyangar Radhika1, Devaraj Ezhilarasan1, Prakasam Gopinath2

*1Radhika MI, Ezhilarasan D, Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha University, Chennai, Tamil Nadu, India*

*2Gopinath P, Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha University, Chennai, Tamil Nadu, India*

**ABSTRACT**

**Objective:** To evaluate the antimicrobial effect of silymarin and silibinin, a plant derived flavonoid compounds against oral microorganisms that are responsible for dental caries.

**Methods:** In the current investigation, we analyzed the comparative antibacterial and antifungal effect of silibinin and silymarin against clinical cariogenic oral pathogens through evaluating their minimum inhibitory and minimum bactericidal concentration. We used clinical isolates that are responsible for dental caries and these include *Candida albicans, Enterococcus faecalis, Lactobacillus acidophilus, Staphylococcus aureus* and *Streptococcus mutans* to evaluate the anticariogenic potential of silymarin and silibinin.

**Results:** In the present investigation, silymarin exhibit good antimicrobial effect against most of the oral cariogenic microorganisms tested when compared to silibinin. Interestingly, silymarin shows high sensitivity at a concentration of <5 µg/ml against *S. mutans, L. acidophilus* and *C. albicans*. On the other hand, silibinin also have significant antimicrobial effect against the oral pathogens.

**Conclusions:** Silymarin and silibinin can be used as appropriate drug candidates that control dental caries, endodontic infections. *J Microbiol Infect Dis 2017; 7(3):139-143*

**Keywords:** silibinin, silymarin, oral infections, oral pathogens

**INTRODUCTION**

The oral cavity contains over and above 600 bacterial species. Oral microorganisms are present generally in the form of a biofilm and sustain ecological equilibrium with the host body. The ecological imbalance of biofilm inexorably manifested as various oral related infectious diseases that include tooth decay, dental caries, gingivitis, thrush, apical periodontitis, periodontal (gum) diseases, pericoronitis, and craniofacial bone osteomyelitis [1]. The ecological imbalance in oral microbiota is also said to an index of systemic diseases and is implicated with several ailments including cancer, diabetes, gastrointestinal diseases, rheumatoid arthritis, cardiovascular diseases, preterm birth and others. The above diseases have strong association with oral health and hence, oral microbiota has been considered as a potential biomarker of human diseases [2,3].

Several strains of oral pathogenic bacteria such as streptococci and lactobacilli are responsible for initiating the formation of dental plaque, which plays an imperative role in the onset of dental caries and other periodontal related diseases in humans [3]. Dental plaque has been said to one of the important etiologic factor in dental caries [4]. The composition of dental plaque, a complex bacterial biofilm is governed by various factors including cell adherence, coaggregation, and growth and survival in the environment [5]. Increasing resistance to these microorganisms against present antimicrobial agents and adverse effects of these drugs is of major cause of concern [6]. Hence, there is an urgent need to develop alternative antimicrobial drugs for the treatment of infections obtained from medicinal plants to counteract the resistance and to minimize the adverse effects. Accordingly, several plant derived compounds have been investigated as promising agents to control and prevent oral ailments, in particular plaque-related diseases such as dental caries [7,8].

Silymarin (SIL) is a standardized extract from the dried seeds of the milk thistle (*Silybum marianum* L. Gaertn.), family Asteraceae. Silymarin contains approximately 70–80% flavonolignans and 20-30% polyphenolic compounds. The mixture of flavonolignans mainly consists of Silibinin (SBN), the major bioactive component of the extract, and isosilybin, silychristin, and silydianin and two flavonoids taxifolin and quercetin [9,10]. Both Silymarin and Silibinin have been reported to have wide spectrum of biological activities. These compounds have been tested for their *in vitro* and *in vivo* antiproliferative, antimicrobial, antiinflammatory, antioxidant, anticancer, free radical scavenging, membrane stabilizing properties and came out with promising results [11-13]. In light of the above reports it is reasonable to assume that the above flavonoids could have antimicrobial activity against oral pathogens. Hence, in this study, we investigated the antibacterial activity of Silymarin and Silibinin against oral bacteria.

**METHODS**

***Drugs***

Silymarin (C25H22O10; CAS No. 65666-07-1) and Silibinin (C25H22O10; CAS No. 22888-70-6) was purchased from Sigma Chemicals, India. It is a mixture of two diastereomers (silybin A and silybin B).

***Clinical Isolates***

Clinical isolates were obtained and experiments were approved by the institutional human ethical committee of Saveetha Dental & Medical College and Hospitals, Saveetha University, Chennai, India.

***Preparation of Stock Solution and Test Solutions***

Stock solutions of Silymarin and Silibinin were prepared at a concentration of 10 mg/ml with dimethylsulfoxide.

***Determination of Minimal Inhibitory Concentration (MIC)***

Antimicrobial activity of SIL and SBN were tested by minimum inhibitory concentration method (MIC) using micro broth dilution method. Briefly, 100 𝜇l of BHI (Brain Heart Infusion, HiMedia) broth was added to each well of 96-well microtitre plate and 100 𝜇l of the stock solutions of SIL and Silibinin were serially diluted to achieve the concentrations ranging from 16 to 0.5 𝜇g/ml. Ten 𝜇l of the 0.5 McFarland standard turbidity adjusted bacterial or yeast suspensions were added to all wells [14]. Well without microorganism served as a control. Then, the plates were incubated at 37º C for 24 h. The assays were done in triplicate. Followed by the next day, 2-3 𝜇l of suspensions from each well were aseptically transferred to the sterile BHIA (Brain Heart Infusion Agar, HiMedia) plates corresponding to the dilutions. The lowest concentration of the Silymarin and Silibinin that completely inhibited the Silymarin growth of isolates in the agar plate was considered as MIC.

**Results**

***Antimicrobial effect of silymarin against oral dental pathogens***

The antimicrobial activity of silymarin showed good inhibitory against *Streptococcus mutans, Lactobacillus acidophilus, Candida albicans.* Silymarin shows MIC value of 1 and 2 µg/ml against *S. mutans* and *L. acidophilus*, respectively. While *Staphylococcus* and *Enterococcus* did not show any change in the maximum concentration tested i.e., 16 µg/ml (Table 2).

***Antimicrobial effect of silibinin against oral dental pathogens***

In this study, Silibinin shows high sensitivity towards the *S. mutans* and *L. acidophilus*. The antimicrobial efficacy against *S. aureus* and *C. albicans* was almost similar i.e., 16 µg/ml. The inhibitory efficacy of Silibinin against *E. faecalis* was not that much prominent with the maximum concentration tested in this study i.e. 16 µg/ml (Table 2).

***Comparative antimicrobial efficacy of SIL and Silibinin against oral dental pathogens***

In this study, we evaluated the antibacterial efficacy of Silymarin and Silibinin against different oral pathogens. We found that Silymarin has high sensitivity *against S. mutans, L. acidophilus*, and *C. albicans* with the MIC of 1, 2, 4 µg/ml, respectively. On the other hand, Silibinin shows MIC values of 4, 8, and 16, respectively. These results clearly indicate the fact that minimal concentration of Silymarin has higher efficacy than that of Silibinin against organisms we tested.

Table 1. List of clinical isolates used.

|  |  |
| --- | --- |
| **Sample No** | **Clinical Isolates** |
| 1 | *Candida albicans* |
| 2 | *Enterococcus faecalis* |
| 3 | *Lactobacillus acidophilus* |
| 4 | *Staphylococcus aureus* |
| 5 | *Streptococcus mutans* |

Table 2. Antimicrobial effect of Silymarin and Silibinin against different clinical isolates.

|  |  |  |  |
| --- | --- | --- | --- |
| **Sample No** | **Organism** | **MIC (µg/ml) Silymarin** | **MIC (µg/ml) Silibinin** |
| 1 | *S. aureus* | >16 | 16 |
| 2 | *E. faecalis* | >16 | >16 |
| 3 | *C. albicans* | 4 | 16 |
| 4 | *L. acidophilus* | 2 | 8 |
| 5 | *S. mutans* | 1 | 4 |

**DISCUSSION**

Oral microbiota is linked with various systemic ailments such as cancer, diabetes, rheumatoid arthritis, cardiovascular diseases, and preterm birth and it is a potential biomarker for these diseases [2]. Regardless of age dental caries is one of the common chronic diseases affects people worldwide and oral bacteria such as L. acidophilus, *E. faecalis* and *S. mutans* are main factor that initiates caries [15].

The incidence of fungal infection has augmented significantly in the past two decades. Among different fungal species Candida is one of the most widespread and threatening fungal pathogens in HIV-infected individuals and it is also responsible for the majority of other invasive and non-invasive fungal infections. Oral candidiasis remains the most common oral lesions in HIV infected patients [16]. Among the Candida species *C. albicans* is responsible for the cause of invasive oral candidiasis, superficial and deep tissue fungal infections [17].

Development of resistance of microorganism against existing antimicrobial agents is one of the causes of concern among scientists and physicians worldwide. Accordingly, various pathogenic microorganisms responsible for diseases are more difficult to treat with the existing drugs [6]. Moreover, some commonly used narrow and broad spectrum antibiotics are associated with various adverse effects on host including hypersensitivity, immune suppression and allergic reactions, drug-drug interaction, photosensitivity, teratogenicity etc., [18]. To overcome the above obstacles in current antimicrobial drugs and to obtain more efficacious drugs with minimal or without any adverse effect, an antimicrobial drug having a novel mode of action should be warranted [19].



Figure 1. Methodology of experiment.

On the other hand, flavonoids are class of plant constituents that have received increasing interest over the last decades. These polyphenols and flavonoids compounds obtained from various medicinal plants have been reported for their beneficial antimicrobial efficacy [20]. It has been reported that some flavonoids compounds are formed in plants as antimicrobial barriers response to microbial infection. Hence, it is not surprising that these flavonoid compounds found in vitro to be effective as an antimicrobial agents against various pathogenic microorganisms [20].

Silymarin, such a plant derived flavonoid compound shows high efficacy against oral dental pathogens tested in this study. It shows more sensitivity against *C. albicans, L. acidophilus* and *S. mutans* in its low concentrations than Silibinin. Silymarin has MIC with <5 µg/ml vs *C. albicans, L. acidophilus* and *S. mutans*, these microorganisms play pivotal role in the onset of dental caries and oral candidiasis. It is reported that these flavonoids have capability to complex with extracellular, soluble proteins and cell wall of microorganism, due to high lipid soluble nature of flavonoids also disrupts bacterial cell wall and fungal membranes [21-23]. The synergistic effect of flavonoids combined with commonly utilized antibiotics is also reported previously [13]. In light of the above reports, it is suggested that the profound antimicrobial efficacy of Silymarin and Silibinin found in this study could be attributed due to their interference with the cell wall of the above tested microorganisms.

It has been reported that systemic C. albicans infections are fatal in 42% of cases [24,25], despite the use of antifungal therapies, and C. albicans is the fourth most common infection in hospitals [26,27]. Fluconazole is a potent and broad-spectrum antifungal agent. It is active against many Candida species. However, it has few side effects and this drug has developed resistance to *C. albicans* over time [28]. In the present study, Silymarin inhibits the growth of *C. albicans* in its low concentration indicate the fact that this drug can be a therapeutic alternative for *C. albicans* infection. However, studies are needed in detail to prove the exact mechanism of action of these plant derived compounds used in this study.

In conclusion, the present study highlights the antimicrobial efficacy of Silymarin and Silibinin. Silymarin and Silibinin can be used as an appropriate drug candidate to control dental caries, endodontic infections.

**Acknowledgments**

**Declaration of Conflicting Interests:** The authors declare that they have no conflict of interest.

**Financial Disclosure:** No financial support was received.

**REFERENCES**

1. Shoji M, Takeshita T, Maruyama F, Inaba H, Imai K, Kawada-Matsuo M. Recent advances in the field of oral bacteriology. Nihon Saikingaku Zasshi 2015;70(2):333-338.

2. Arweiler NB, Netuschil L. The Oral Microbiota. Adv Exp Med Biol 2016; 902:45-60.

3. Sangeetha S, Ezhilarasan D. In vitro antimicrobial activity of dandelion against orodental pathogens. IJPPR 2016;8(10);1598-1600.

4. Kim JH. Anti-bacterial action of onion (Allium cepa L.) extracts against oral pathogenic bacteria. J Nihon Univ Sch Dent 1997;39(3):136-141.

5. Korkina LG, Mikhal'chik E, Suprun MV, Pastore S, Dal Toso R. Molecular mechanisms underlying wound healing and anti-inflammatory properties of naturally occurring biotechnologically produced phenylpropanoid glycosides. Cell Mol Biol (Noisy-le-grand) 2007; 53(5):84-91.

6. Corona F, Blanco P, Alcalde-Rico M, et al. The analysis of the antibiotic resistome offers new opportunities for therapeutic intervention. Future Med Chem 2016; 8(10):1133-1151.

7. Cha JD, Jeong MR, Jeong SI, et al. Chemical composition and antimicrobial activity of the essential oil of Cryptomeria japonica. Phytother Res 2007; 21(3):295-299.

8. Dahot MU. Antibacterial and antifungal activity of small protein of Indigofera oblongifolia leaves. J Ethnopharmacol 1999; 64(3):277-282.

9. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol 2011;17(18):2288-2301.

10. Morazzoni P, Bombardelli E. Silybum marianum (Carduus marianus). Fitoterapia 1995; 66(1):3-42.

11. Ezhilarasan D, Evraerts J, Sid B, et al. Silibinin inhibits proliferation and migration of human hepatic stellate LX-2 cells. J Clin Exp Hepatol 2016;6(3): 167-174.

12. Ezhilarasan D, Karthikeyan S. Silibinin alleviates N-nitrosodimethylamine-induced glutathione dysregulation and hepatotoxicity in rats. Chin J Nat Med 2016;14(1):40-47.

13. de Oliveira DR, Tintino SR, Braga MF, et al. In vitro antimicrobial and modulatory activity of the natural products silymarin and silibinin. Biomed Res Int 2015;2015:292797.

14. Shah PM. Determination of MICs in the routine laboratory. J Antimicrob Chemother 2001; 48(6):931.

15. Anita P, Sivasamy S, Madan Kumar PD, Balan IN, Ethiraj S. In vitro antibacterial activity of Camellia sinensis extract against cariogenic microorganisms. J Basic Clin Pharm 2014;6(1):35-9.

16. Nittayananta W. Oral fungi in HIV: challenges in antifungal therapies. Oral Dis 2016;22 Suppl 1:107-13.

17. Pemán J, Quindós G. Current aspects of invasive diseases caused by Candida and other yeast fungi. Rev Iberoam Micol 2016.

18. Khanahmadi M, Rezazadeh SH, Taran M. In vitro antimicrobial and antioxidant properties of Smyrnium cordifolium Boiss. (Umbelliferae) extract. Asian J Plant Sci 2010;9:99-103.

19. Khalafi-Nezhada A, Soltani Rada MN, Mohabatkarb H, Asraria Z, Hemmateenejada B. Design, synthesis, antibacterial and QSAR studies of benzimidazole and imidazole chloroaryloxyalkyl derivatives Bioorg Med Chem 2005;13(6):1931-38.

20. Orhan DD, Ozçelik B, Ozgen S, Ergun F. Antibacterial, antifungal, and antiviral activities of some flavonoids. Microbiol Res 2010; 165(6):496-504.

21. Cushnie TPT, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents 2005;26(5):343-56.

22. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev 1999;12(4):564-82.

23. Tsuchiya H, Sato M, Miyazaki T, et al. Comparative study on the antibacterial activity of phytochemical flavanones against methicillin-resistant Staphylococcus aureus. J Ethnopharmacol 1996; 50(1):27-34.

24. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003;22(8):686-91.

25. Ford CB, Funt JM, Abbey D, et al. The evolution of drug resistance in clinical isolates of Candida albicans. Elife 2015;4:e00662.

26. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37(9):1172-177.

27. Pappas PG, Rex JH, Lee J, et al. NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37(5):634-43.

28. Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol 2012; 2012:713687.